Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listDasatinib monohydrate

Dasatinib monohydrate

  • CAS NO.:863127-77-9
  • Empirical Formula: C22H28ClN7O3S
  • Molecular Weight: 506.02
  • MDL number: MFCD08704581
  • EINECS: 638-874-6
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-19 15:53:33
Dasatinib monohydrate Structural

What is Dasatinib monohydrate?

The Uses of Dasatinib monohydrate

Dasatinib Monohydrate is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. It is a COVID19-related research product.

The Uses of Dasatinib monohydrate

antineoplastic

What are the applications of Application

Dasatinib (monohydrate) is an inhibitor of Src family kinases, including c-Abl and Bcr-Abl tyrosine kinase activity

Definition

Dasatinib monohydrate is a hydrate that is the monohydrate of dasatinib. It is used for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN; dasatinib monohydrate) as well as to anhydrous dasatinib (INN). It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It contains a dasatinib (anhydrous).

brand name

Sprycel (Bristol-Myers Squibb).

Biological Activity

chronic myeloid leukemia (cml) is a disease characterized by the presence of the philadelphia (ph+) chromosome and its oncogenic product, bcr-abl, that is present in >90% of the patients. dasatinib (bms-354825) is a novel, potent, and multitargeted kinase inhibitor that targets abl, src, kit, pdgfr, and other tyrosine kinases.

in vitro

dasatinib is a potent atp-competitive inhibitor in biochemical assays with broad-spectrum antiproliferative activities against hematological and solid tumor cell lines. dasatinib was more potent than imatinib at inhibiting nonmutated bcr-abl kinase activity. in addition, the kinase activity of 14 out of 15 different clinically relevant, imatinib-resistant bcr-abl isoforms was successfully inhibited [1].

in vivo

mice were dosed with dasatinib or vehicle alone by gavage for 2 weeks, beginning 3 days after injection of ba/f3 cells. all vehicle-treated mice developed progressive disease. in contrast, dasatinib–treated mice harboring nonmutant bcr-abl or the clinically common imatinib-resistant mutation m351t appeared healthy with no evidence of weight loss, lethargy, or ruffled fur and showed more than one log lower levels of bioluminescent activity after 2 weeks of therapy [2].

References

[1] shah np, tran c, lee fy, chen p, norris d, sawyers cl. overriding imatinib resistance with a novel abl kinase inhibitor. science. 2004 jul 16;305(5682):399-401.
[2] monika conchon, carla maria boquimpani de moura freitas, maria aparecida do carmo rego, and josé wilson ramos braga junior. dasatinib -

Properties of Dasatinib monohydrate

Melting point: >223° (dec.)
storage temp.  Keep in dark place,Sealed in dry,Store in freezer, under -20°C
solubility  DMSO (Slightly, Sonicated), Methanol (Slightly, Sonicated)
form  Solid
color  White to Off-White
Stability: Hygroscopic
CAS DataBase Reference 863127-77-9(CAS DataBase Reference)

Safety information for Dasatinib monohydrate

Computed Descriptors for Dasatinib monohydrate

InChIKey XHXFZZNHDVTMLI-UHFFFAOYSA-N
SMILES N(C1=NC=C(C(=O)NC2C(=CC=CC=2C)Cl)S1)C1N=C(C)N=C(N2CCN(CCO)CC2)C=1.O

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.